182 related articles for article (PubMed ID: 36409389)
1. Fc receptor-like 1 (FCRL1) is a novel biomarker for prognosis and a possible therapeutic target in diffuse large B-cell lymphoma.
Yousefi Z; Sharifzadeh S; Zare F; Eskandari N
Mol Biol Rep; 2023 Feb; 50(2):1133-1145. PubMed ID: 36409389
[TBL] [Abstract][Full Text] [Related]
2. Fc Receptor-Like 1 as a Promising Target for Immunotherapeutic Interventions of B-Cell-Related Disorders.
Yousefi Z; Sharifzadeh S; Yar-Ahmadi V; Andalib A; Eskandari N
Biomark Insights; 2019; 14():1177271919882351. PubMed ID: 31798301
[TBL] [Abstract][Full Text] [Related]
3. Elevated RNA expression of long non‑coding HOTAIR promotes cell proliferation and predicts a poor prognosis in patients with diffuse large B cell lymphoma.
Yan Y; Han J; Li Z; Yang H; Sui Y; Wang M
Mol Med Rep; 2016 Jun; 13(6):5125-31. PubMed ID: 27122348
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
[TBL] [Abstract][Full Text] [Related]
5. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling.
Yang J; Li Y; Zhang Y; Fang X; Chen N; Zhou X; Wang X
J Exp Clin Cancer Res; 2020 Jul; 39(1):142. PubMed ID: 32711549
[TBL] [Abstract][Full Text] [Related]
6. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
Zhao MY; Auerbach A; D'Costa AM; Rapoport AP; Burger AM; Sausville EA; Stass SA; Jiang F; Sands AM; Aguilera N; Zhao XF
Clin Cancer Res; 2009 Mar; 15(5):1708-20. PubMed ID: 19223503
[TBL] [Abstract][Full Text] [Related]
7. CDC6, a key replication licensing factor, is overexpressed and confers poor prognosis in diffuse large B-cell lymphoma.
Shen M; Zhang Y; Tang L; Fu Q; Zhang J; Xu Y; Zeng H; Li Y
BMC Cancer; 2023 Oct; 23(1):978. PubMed ID: 37833632
[TBL] [Abstract][Full Text] [Related]
8. Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma.
Cui W; Cai Y; Wang W; Liu Z; Wei P; Bi R; Chen W; Sun M; Zhou X
J Transl Med; 2014 Jan; 12():10. PubMed ID: 24418330
[TBL] [Abstract][Full Text] [Related]
9. Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activation.
Knies N; Alankus B; Weilemann A; Tzankov A; Brunner K; Ruff T; Kremer M; Keller UB; Lenz G; Ruland J
Proc Natl Acad Sci U S A; 2015 Dec; 112(52):E7230-8. PubMed ID: 26668357
[TBL] [Abstract][Full Text] [Related]
10. β-TrCP1 promotes cell proliferation via TNF-dependent NF-κB activation in diffuse large B cell lymphoma.
Cai N; Chen Z; Huang Y; Shao S; Yu H; Wang Y; He S
Cancer Biol Ther; 2020; 21(3):241-247. PubMed ID: 31731887
[TBL] [Abstract][Full Text] [Related]
11. PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells.
Zhu F; Guo H; Bates PD; Zhang S; Zhang H; Nomie KJ; Li Y; Lu L; Seibold KR; Wang F; Rumball I; Cameron H; Hoang NM; Yang DT; Xu W; Zhang L; Wang M; Capitini CM; Rui L
Leukemia; 2019 Dec; 33(12):2898-2911. PubMed ID: 31123343
[TBL] [Abstract][Full Text] [Related]
12. The biological and clinical impact of inhibition of NF-κB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL).
Bavi P; Uddin S; Bu R; Ahmed M; Abubaker J; Balde V; Qadri Z; Ajarim D; Al-Dayel F; Hussain AR; Al-Kuraya KS
J Pathol; 2011 Jul; 224(3):355-66. PubMed ID: 21506127
[TBL] [Abstract][Full Text] [Related]
13. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
[TBL] [Abstract][Full Text] [Related]
14. PIK3CD promoted proliferation in diffuse large B cell lymphoma through upregulation of c-myc.
Cui W; Zheng S; Li X; Ma Y; Sang W; Liu M; Zhang W; Zhou X
Tumour Biol; 2016 Sep; 37(9):12767-12777. PubMed ID: 27448819
[TBL] [Abstract][Full Text] [Related]
15. Defining causative factors contributing in the activation of hedgehog signaling in diffuse large B-cell lymphoma.
Ramirez E; Singh RR; Kunkalla K; Liu Y; Qu C; Cain C; Multani AS; Lennon PA; Jackacky J; Ho M; Dawud S; Gu J; Yang S; Hu PC; Vega F
Leuk Res; 2012 Oct; 36(10):1267-73. PubMed ID: 22809693
[TBL] [Abstract][Full Text] [Related]
16. Chidamide and orelabrutinib synergistically induce cell cycle arrest and apoptosis in diffuse large B-cell lymphoma by regulating the PI3K/AKT/mTOR pathway.
Wu C; Chen S; Wu Z; Xue J; Zhang W; Wang S; Xindong Zhao ; Wu S
J Cancer Res Clin Oncol; 2024 Feb; 150(2):98. PubMed ID: 38381215
[TBL] [Abstract][Full Text] [Related]
17. SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway.
Takagi Y; Shimada K; Shimada S; Sakamoto A; Naoe T; Nakamura S; Hayakawa F; Tomita A; Kiyoi H
Cancer Sci; 2016 Sep; 107(9):1270-80. PubMed ID: 27348272
[TBL] [Abstract][Full Text] [Related]
18. Single-cell RNA sequencing in double-hit lymphoma: IMPDH2 induces the progression of lymphoma by activating the PI3K/AKT/mTOR signaling pathway.
Gao G; Xue Q; He J; Wu M; Jiang Y; Li Q; Zhang Y; Shi W
Int Immunopharmacol; 2023 Dec; 125(Pt A):111125. PubMed ID: 37907047
[TBL] [Abstract][Full Text] [Related]
19. Trimeric G protein-CARMA1 axis links smoothened, the hedgehog receptor transducer, to NF-κB activation in diffuse large B-cell lymphoma.
Qu C; Liu Y; Kunkalla K; Singh RR; Blonska M; Lin X; Agarwal NK; Vega F
Blood; 2013 Jun; 121(23):4718-28. PubMed ID: 23632891
[TBL] [Abstract][Full Text] [Related]
20. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.
Lam LT; Davis RE; Pierce J; Hepperle M; Xu Y; Hottelet M; Nong Y; Wen D; Adams J; Dang L; Staudt LM
Clin Cancer Res; 2005 Jan; 11(1):28-40. PubMed ID: 15671525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]